Heidelberg Pharma AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Heidelberg Pharma AG
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
The mid-sized pharmaceutical company Norgine aims to grow its specialty business in Europe through targeted business development activities, while at the same time separating out its consumer healthcare activities into a new subsidiary.
Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Heidelberg Pharma Research GmbH
- Wilex AG